A multicenter study comparing treatment of patients with neuroendocrine gastro-entero-pancreatic (GEP) tumours with 177Lu-octreotate [Octreotate-Lu-177-DOTA-Tyr-3] versus combined 177Lu-octreotate and capecitabine treatment
Phase of Trial: Phase III
Latest Information Update: 16 Sep 2011
At a glance
- Drugs Capecitabine (Primary) ; Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 01 Mar 2010 Status changed from planning to completed as reported by ISRCTN: Current Controlled Trials.
- 01 Mar 2007 New trial record.